The Patent Finder

Imclone LLC

4 patents currently held · Updated Nov 17, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Oct 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 4 of 4

PatentTitleStatus Expires Confidence
US 7,598,350Human Anti-Epidermal Growth Factor Receptor Antibody
In force
 · High confidence
In forceHigh confidence
US 8,481,034Anti-VEGFR-3 antibody compositions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,552,157c-Kit antibodies and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,766,961ANTI-VEGFR2 Antibody Therapy for Hepatocellular Carcinoma
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 1 patent in force now held by others · 19 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 abandoned · 9 no status recorded

Showing 1 to 10 of 13, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
17/091,552Nov 6, 2020No status recorded
16/493,070Mar 9, 2018No status recorded
16/339,776Combination of an ANTI-VEGFR-2 Antibody and an ANTI-PD-L1 Antibody for the Treatment of CancerOct 27, 2017Abandoned
16/330,128Combination Therapy for CancerSep 7, 2017Abandoned
16/305,327Combination of Ramucirumab and Pembrolizumab for the Treatment of Certain CancersMay 26, 2017Abandoned
15/590,042May 9, 2017No status recorded
15/745,451Aug 10, 2016No status recorded
15/318,376Jun 26, 2015No status recorded
15/318,370Jun 26, 2015No status recorded
13/400,308Feb 20, 2012No status recorded
10 of 13 applications shown.
Pro members see all 13 published applications.
Pro members: see all 13 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited